Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
Phase 2 N=44 D-serine for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03
Phase 3 N=8 Glycine vs Placebo for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale
N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
Phase 4 N=26 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
Phase 1 N=71 Metabolic Signatures and Biomarkers in Schizophrenia
Schizophrenia
Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
N/A N=538 Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia
Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001
Phase 4 N=628 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not…
N/A N=50 Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
Attenuated Psychosis Syndrome
Primary: Brain Volume — 19.8; 54.8; -0.489; -6.28 Change in mm cubed (baseline -followup)
N/A N=59 Cognitive Rehabilitation in Schizophrenia
Cognitive Impairment · Schizophrenia
Primary: Wisconsin Card Sort Percent Perseverative Errors (Standard Score) — 87.54; 87.88; 91.80 standard score units — p=<.97
Phase 2 N=12 Effects of Galantamine on Cognition
Schizophrenia
Primary: RVIP Target Hit and False Alarm (Number of Responses) — 23.4; 22.8; 19.7; 14.88 Number of responses — p=0.898
N/A N=24 rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 3 N=49 Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score — -10.2 Units on a scale — p=<0.0001
N/A N=121 Nicotine Effects on Endophenotypes of Schizophrenia
Schizophrenia
Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
N/A N=21 Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
Schizophrenia
Primary: Mean Score on the Scale for the Assessment of Negative Symptoms (SANS), p=0.048 — -10.38; -2.33 units on a scale — p=.048
Phase 4 N=29 Modafinil Effects on Cognition in Schizophrenia Patients
Schizophrenia
Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials
N/A N=8 Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia
Schizophrenia · Psychosis
Primary: tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging
Phase 4 N=33 Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task — 8.6; 9.2 percent change in accuracy
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Phase 2 N=88 Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 30.92; 30.32; 33.43; 32.76 T score
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
Phase 2 N=224 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Schizophrenia, Acute Episode
Primary: Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -14.6; -17.2; -10.0 Score on a Scale — p=0.440